Latest Myeloproliferative disease Stories
- CYT387 suppresses multiple signaling pathways, prevents proliferation and induces apoptosis in myeloma cells - - Results published in July online edition of Leukemia - MISSISSAUGA, ON, Aug. 4, 2011 /PRNewswire/ - YM BioSciences Inc.
WHITE PLAINS, N.Y., July 18, 2011 /PRNewswire/ -- The Leukemia & Lymphoma Society (LLS) today announced it has awarded two new Marshall A. Lichtman Specialized Center of Research (SCOR) grants to Frederick W.
VENLO, The Netherlands, June 15, 2011 /PRNewswire/ -- - QIAGEN in exclusive negotiations to purchase 47% initial stake in Ipsogen S.A.and then fully acquire a global leader in hematologic (blood) cancer molecular diagnostics - Ipsogen has a competitive portfolio in blood cancer testing with assays covering 15 biomarkers-including BCR-ABL and JAK2 -for patient profiling and monitoring - Many of Ipsogen's assays...
- Poster with broader update of trial results to be presented at ASCO - MISSISSAUGA, ON, May 18 /PRNewswire-FirstCall/ - YM BioSciences Inc.
MISSISSAUGA, ON, April 18 /PRNewswire/ - YM BioSciences Inc. (NYSE Amex: YMI, TSX: YM), today announced that updated interim anemia response data were reported for the first 60 patients enrolled in the Phase I/II trial of its JAK1/JAK2 inhibitor, CYT387, for the treatment of myelofibrosis.
In response to blood cancer re-classifications by the World Health Organization, the MPD Foundation announces it is changing its name to Myeloproliferative Neoplasms (MPN) Research Foundation. Chicago, IL (PRWEB) April 4, 2011 The MPD Foundation, a patient-led foundation dedicated to the discovery of treatments and a cure for three rare blood cancers (myelofibrosis, polycythemia vera, and essential thrombocythemia) announces today a new name for the organization, which will now be known as...
Over the past decade, significant advances have been made in the treatment of leukemia through the ongoing development of gene-based targeted therapies.
SINGAPORE, Dec. 6, 2010 /PRNewswire/ -- S*BIO Pte Ltd today announced that data from Phase 1/2 studies for its novel JAK2 inhibitor SB1518 indicates clinical efficacy and good tolerability for the treatment of patients with symptomatic myelofibrosis (MF) and enlarged spleens.
Company to discuss interim results from Phase I/II trial of CYT387 being presented today at the 52(nd) American Society of Hematology Annual Meeting ORLANDO, Dec. 6 /PRNewswire-FirstCall/ - YM BioSciences Inc.
- totally perplexed and mixed up.